Systemic sclerosis (SSc) is an autoimmune rheumatic disease where vasculopathy is one of the main hallmarks, and the gastrointestinal (GI) tract is one of the most affected systems [1,2]. In fact, SSc is characterized by esophageal dysfunction, gastro-esophageal reflux disease (GERD), visceral dysmotility, bowel distention and small intestinal bacterial overgrowth syndrome (SIBO), and complete loss of bowel motility [3]. Currently there are no standardized guidelines to assess and manage SSc-related GI involvement, however in recent years the understanding of SSc-related GI disease has grown both for an early diagnosis and management of its complications [4].
